It has been shown in a mouse model of lung cancer that treatment with FAPα-specific CAR T cells in concurrence with T cells targeting a tumor specific TAA, namely ephrin type-A receptor 2, could significantly enhance the anti-tumor effect compared to separate administration of these gene-engineered T cells [97]. The gene discussed is FAP; the disease is neoplasm.